Tenderwize
Retour à la recherche

Open House Originale Contract for Sofosbuvir/Velpatasvir/Voxilaprevir

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 369 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (Wirkstoffkombination)

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Only pharmaceutical undertakings for the relevant medicines, with the required seat and marketing authorisation, may pa...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply/rebate contract for pharmaceutical products concerning the combination Sofosbuvir, Velpatasvir, Voxilaprevir.
  • Nationwide performance in Germany.
Afficher le résumé complet

Open House-style pharmaceutical supply arrangement by Techniker Krankenkasse for the fixed combination Sofosbuvir/Velpatasvir/Voxilaprevir. The notice states there is no exclusivity, no individual negotiation, and contracts can be joined at any time during the term. The contract term runs from 2025-09-01 to 2027-08-31 at the latest, with earlier automatic end if patent/market exclusivity expires. No contract value is stated. Participation is restricted to pharmaceutical companies meeting the stated legal and self-declaration requirements, and submission is not via the portal but by email or post.

Risques

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Only pharmaceutical undertakings for the relevant medicines, with the required seat and marketing authorisation, may pa...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG for the relevant medicines.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicines or otherwise be entitled to place them on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Contract for Sofosbuvir/Velpatasvir/Voxilaprevir

Single lot covering rebate contracts for the medicinal product combination Sofosbuvir, Velpatasvir, Voxilaprevir. Scope is nationwide in Germany. The notice says the arrangement is open to all suitable pharmaceutical companies, with uniform conditions, no exclusivity, and no individual negotiations. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 30, 2027

Détails de la procédure

Date de publication
22 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
481017-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3